-
Front Oncol: High serum OPG level is a poor prognostic factor for patients with hepatocellular carcinoma (HCC)
Time of Update: 2021-10-10
In summary, studies have shown that high serum osteoprotegerin (OPG) levels are a poor prognostic factor for patients with hepatocellular carcinoma (HCC) .
Studies have shown that high serum osteoprotegerin (OPG) levels are a poor prognostic factor for patients with hepatocellular carcinoma (HCC) .
-
Br J Cancer: Long-term risk assessment of combined radiotherapy after breast-conserving surgery for ductal carcinoma in situ of the breast
Time of Update: 2021-10-10
The study aims to evaluate the impact of DCIS treatment on the 20-year risk of ipsilateral DCIS (iDCIS) and ipsilateral invasive breast cancer (iIBC) in a population-based cohort .
-
Front Oncol: Li Qi's team study the efficacy of Chinese medicine formula PRM1201 combined with chemotherapy in adjuvant treatment of stage III colon cancer patients: a randomized, double-blind, placebo-controlled study
Time of Update: 2021-10-10
618793Jia R, Liu N, Cai G, et al (2021) Effect of PRM1201 Combined With Adjuvant Chemotherapy on Preventing Recurrence and Metastasis of Stage III Colon Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
-
Case sharing Abiraterone continues to relieve PSA deeply, and the quality of the original research is more guaranteed
Time of Update: 2021-10-10
Prostate cancer is a serious threat to the health of middle-aged and elderly men in China. Among them, the diagnosis and treatment of metastatic hormone-sensitive prostate cancer (mHSPC) is complica
-
Lancet Oncol: Apalutamide combined with abiraterone-prednisone can significantly improve the survival prognosis of mCRPC patients
Time of Update: 2021-10-10
In summary, compared with standard therapies, apalutamide combined with abiraterone-prednisone can improve the radiological progression-free survival of newly treated mCRPC patients .
Compared with standard therapy, apalutamide combined with abiraterone-prednisone can improve the radiological progression-free survival of newly treated mCRPC patients.
-
Chongqing Precision Bio-C-4-29 cell preparations for renal cell carcinoma solid tumor indications obtained implied approval from clinical trials
Time of Update: 2021-10-10
Click on the picture to sign up for the conference September 29, 2021 / eMedClub News/---September 28, 2021, Chongqing Precision Bio's innovative CAR-T product C-4-29 cell preparation targeted therapy "CD70 expression" The “positive advanced renal cell carcinoma” indication has been approved by the NMPA clinical trial .
-
Front Oncol: Comparison of response and prognosis of KRAS G12C mutation and other subtypes in patients with metastatic colorectal cancer (mCRC) using standard first-line treatment
Time of Update: 2021-10-10
Among patients with first-line standard treatment of mCRC, patients with KRAS G12C mutation had a lower response rate compared with other mutation subtypes, and there was no statistical difference in median PFS and OS .
-
Molecular Cancer Hejie academician team revealed for the first time the molecular characteristics, immuno-oncology characteristics and clinical relevance of m6A regulatory factors in small cell lung cancer
Time of Update: 2021-10-10
The addition of immune checkpoint inhibitors to conventional chemotherapy for small cell lung cancer is promising; however, their absolute long-term benefits are moderate .
-
Nature sub-news: Alcohol "reduced" longevity, curcumin to remedy!
Time of Update: 2021-10-10
This study did not observe any significant effect of any test compound on the DNA methylation level; however, when the bees were fed ethanol alone, a hypermethylation trend was indeed observed .
-
Gastric Cancer: The efficacy and safety of nivolumab in the treatment of unresectable advanced or recurrent gastric/gastric junction cancer (G/GEJ): real research data from Japan
Time of Update: 2021-10-10
Recently, a team from Japan conducted a real-world study to evaluate the efficacy and safety of nivolumab treatment in patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer (G/GEJ) that has progressed after chemotherapy (≥2 lines) .
-
The world’s first ADC drug targeting CD19, Loncastuximab tesirine, launched a key phase II study, and completed the first patient administration in a clinical trial in China
Time of Update: 2021-10-10
2021 Nian 9 Yue 29 days, by the way Ling Pharmaceutical and ADC Therapeutics creation of a joint venture Ling Luaidisi announced, carried out in China Loncastuximab tesirine for relapsed / refractory diffuse large B cell lymphoma ( lymphoma r / r DLBCL ) in a pivotal phase II clinical trial completed the first patient dosing .
-
Front Oncol: Exploration of the efficacy of different treatment strategies for patients with MET amplification after EGFR-TKI treatment progresses in EGFR-mutant NSCLC patients
Time of Update: 2021-10-10
Efficacy and prognosisEfficacy and prognosisThe median real-world PFS (rwPFS) of patients receiving EGFR-TKI combined with crizotinib was compared with crizotinib monotherapy (5.
The median real-world PFS (rwPFS) of patients receiving EGFR-TKI combined with crizotinib was compared with crizotinib monotherapy (5.
-
Is osimertinib resistant because it transformed into large-cell neuroendocrine cancer?
Time of Update: 2021-10-10
The Journal of Medical Case Reports reported a rare case of a patient with EGFR T790M mutation lung adenocarcinoma who transformed into large cell neuroendocrine carcinoma (LCNEC) after treatment with osimertinib [4], which provides another opportunity for the treatment of osimertinib resistance.
-
The domestically-developed original drug Fruquintinib-to solve the dilemma of the late-line treatment of metastatic colorectal cancer
Time of Update: 2021-10-10
*Only for medical professionals to read and refer to the light of domestically developed anti-cancer: The real world study results of Fruquintinib for third-line and later treatment of Chinese patients with metastatic colorectal cancer have been announced .
-
2021 CSCO Professor Li Jin: The Phase I study data of MRG002 is officially announced, ADC drugs and immunotherapy are in the ascendant
Time of Update: 2021-10-10
Professor Li Jin from Dongfang Hospital of Tongji University participated in the conference as the chairperson of the special session on gastrointestinal tumors, and published the title "Evaluation of Recombinant Humanized Anti-HER2 Mab-MMAE Conjugate for Injection (MRG002) in Patients with HER2+ Advanced Solid Tumors An important report on the safety, tolerability of dose escalation and expansion of clinical studies into the group" .
-
Liu Xiaole's team "Cell" published an article to find a new treatment target for refractory breast cancer!
Time of Update: 2021-10-10
According to the team’s latest research published in Cell, their CRISPR/Cas9 knockout library MusCK can target 4500 mouse genes, which are all related to tumor initiation, development and immune regulation .
-
The Oncologist: Comparison of the efficacy of FTD/TPI and regorafenib in the treatment of patients with advanced colorectal cancer
Time of Update: 2021-10-10
001 oncologist>001-->The study included eligible patients from 2012 to 2017 and compared the real-world objective response rate (rwORR), the real-world disease control rate (rwDCR), and survival .
The study included eligible patients from 2012 to 2017 and compared the real-world objective response rate (rwORR), the real-world disease control rate (rwDCR), and survival .
-
Clin Cancer Res: New immunotherapy is out!
Time of Update: 2021-10-10
The relevant research results were published under the title "Memory-like Differentiation Enhances NK Cell Responses to Melanoma" In the journal "Clinical Cancer Research" .
Therefore, in this new study, the researchers tested the therapeutic effect of melanoma patients after NK cells were differentiated into memory-like NK cells .
-
CSCO 2021: In the era of targeted immunotherapy, new thinking on radiotherapy for liver cancer
Time of Update: 2021-10-10
A single high-dose radiation irradiation promotes the polarization of surrounding macrophages to the tumor suppressor M1 type, thereby increasing the immune effect after radiotherapy .
A single high-dose radiation irradiation promotes the polarization of surrounding macrophages to the tumor suppressor M1 type, thereby increasing the immune effect after radiotherapy .
-
Ruguang was born, in the name of the mountain, cracked the code of the otuzumab literature and played the life movement of Chinese FL patients!
Time of Update: 2021-10-10
The emergence of a new type of humanized glycosylation modified type II anti-CD20 mAb-Otuzumab has brought changes in the treatment of FL patients .
A number of studies have shown that otuzumab significantly improves the efficacy of FL patients and brings new hope for the treatment of FL patients .
